◼ Archived
Business
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte stock surges following phase 3 trial results for its pneumococcal vaccine candidate in a lucrative market.
1 trends tracked about this subject — the full history, oldest to newest below.
Vaxcyte stock surges following phase 3 trial results for its pneumococcal vaccine candidate in a lucrative market.